"The toxicity profiling of biological molecules or biopharmaceuticals during the regulatory preclinical development is divided in two blocks, one consisting in a series of preliminary toxicity studies like the Dose Range Finder (DRF), the Maximum Tolerated Dose (MTD) and an early assessment of the pharmacokinetic behavior associated or not with a pharmacodynamic assessment. Most of those studies performed at this stage of the toxicity profiling are not required to be performed under Good Laboratory Practice.
OMICS Group International is one of the leading Open Access Publishers which is publishing 700+ peer-reviewed journals with the support of 50,000+ editorial board members as editorial team and aimed to disseminate the scholarly knowledge to the scientific society. OMICS Group also organizing 3000+ International Scientific Conferences and events yearly all over the world with the support of 1000+ Scientific associations worldwide.
Citation: Maraschiello C (2014) The Relevance of Immunogenicity in Preclinical development. J Bioanal Biomed 6: 001-004."
Last date updated on June, 2021